Merck
  • Home
  • Search Results
  • Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques.

Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques.

Molecular therapy : the journal of the American Society of Gene Therapy (2017-09-30)
Frank Liang, Gustaf Lindgren, Ang Lin, Elizabeth A Thompson, Sebastian Ols, Josefine Röhss, Shinu John, Kimberly Hassett, Olga Yuzhakov, Kapil Bahl, Luis A Brito, Hugh Salter, Giuseppe Ciaramella, Karin Loré
ABSTRACT

mRNA vaccines are rapidly emerging as a powerful platform for infectious diseases because they are well tolerated, immunogenic, and scalable and are built on precise but adaptable antigen design. We show that two immunizations of modified non-replicating mRNA encoding influenza H10 hemagglutinin (HA) and encapsulated in lipid nanoparticles (LNP) induce protective HA inhibition titers and H10-specific CD4

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
N-Acetyl-D-lactosamine, ≥98%